The prognosis and survival in endometrial cancer depend to a much degree on disease stage as determined by intraoperative findings and histology study. Lymph node involvement is the most important prognostic factor in early endometrial cancer. Poor prognosis factors statistically significantly influencing follow-up outcomes in clinical stage I-III endometrial cancer include disease stage, patient age, depth of myometrial invasion, degree of tumor differentiation, tumor size, the presence of dissemination, lymphogenic metastasis, myometrial blood and lymph vascular involvement, positive abdominal lavage.

Prognosis and survival in patients with endometrial cancer depend mainly on disease stage as determined by intraoperative findings and histology study. Poor prognosis factors statistically significantly influencing follow-up outcomes in clinical stage I-III endometrial cancer include disease stage, patient age, depth of myometrial invasion, degree of tumor differentiation, the presence of myometrial blood and lymph vascular involvement, positive abdominal lavage, tumor size, the presence of metastatic disease, lymphogenic metastasis. Lymph node involvement is the most important factor of prognosis in early endometrial cancer.

Treatment outcomes were assessed in 120 patients with stage 0-IV adenocarcinoma of the uterine cervix. Clinical course of adenocarcinoma of the uterine cervix was characterized by tumor location in the cervical canal (70.8% of cases), endophytic or mixed tumor growth (73.3%), mucinous or endometrioid adenocarcinoma type (92.5%). Pelvic lymph node involvement was encountered in 34.0% of cases. Principal factors of poor prognosis in adenocarcinoma of the uterine cervix were disease stage, total cervix involvement, mixed type of tumor growth, more than 5 mm cervical stroma invasion, regional lymph node involvement and tumor necrosis. Adequate treatments of patients with adenocarcinoma of the uterine cervix include surgery with extirpation of the uterus and the vaginal upper third in stage 0-IA1, wide extirpation of the uterus in stage IA2, combined modality treatment (wide extirpation of the uterus plus radiotherapy) in stage IB-IIA and radical combination radiotherapy in stage IIB-III (T3) disease.